Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell 4Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Recurrence 2Lymphoma, T-Cell, Peripheral 2Leukemia 2Squamous Cell Carcinoma of Head and Neck 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Lymphoma, Follicular 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Head and Neck Neoplasms 1Enteropathy-Associated T-Cell Lymphoma 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 192Methotrexate 106Cytarabine 86fludarabine phosphate 80Busulfan 71Tacrolimus 70Peripheral Blood Stem Cell Transplantation 69Mycophenolic Acid 69Whole-Body Irradiation 68Vincristine 67fludarabine 61Filgrastim 61Etoposide 59Dexamethasone 54Melphalan 52Radiotherapy 47Rituximab 46Cyclosporine 46Doxorubicin 38Antilymphocyte Serum 37Thiotepa 35Prednisone 35Mercaptopurine 35Granulocyte Colony-Stimulating Factor 35blinatumomab 33pegaspargase 27Methylprednisolone 27Daunorubicin 26Clofarabine 26Asparaginase 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × duvelisib × Clear all
NCT02028039 2014-01-06

IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)

M.D. Anderson Cancer Center

Phase 2 Withdrawn
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡